LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway

References

• Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 2017;10(1):5–12.
   PubMedGoogle Scholar
• Sebesta EM, Anderson CB. The surgical management of prostate cancer. Semin Oncol. 2017;44(5):347–357. doi:10.1053/j.seminoncol.2018.01.003
   PubMed Web of Science ®Google Scholar
• Mansinho A, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: mechanisms, targets and treatment. Adv Exp Med Biol. 2018;1096:117–133.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15(2):194–202. doi:10.1158/1055-9965.EPI-05-0011
   PubMed Web of Science ®Google Scholar
• Kim SH, Das K, Noreen S, Coffman F, Hameed M. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol. 2007;5(1):17. doi:10.1186/1477-7819-5-17
   PubMedGoogle Scholar
• Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer. 2002;95(2):267–274. doi:10.1002/cncr.10644
   PubMed Web of Science ®Google Scholar
• Høgdall EV, Ringsholt M, Høgdall CK, et al. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer. 2009;9(1):8. doi:10.1186/1471-2407-9-8
   PubMedGoogle Scholar
• Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer. 2004;46(3):333–340. doi:10.1016/j.lungcan.2004.05.010
   PubMed Web of Science ®Google Scholar
• Özdemir E, Çiçek T, Kaya MO. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer. Urol J. 2012;9(3):568–573.
   PubMed Web of Science ®Google Scholar
• Coskun U, Yamac D, Gulbahar O, Sancak B, Karaman N, Ozkan S. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?. Neoplasma. 2007;54(4):348–352.
   PubMed Web of Science ®Google Scholar
• Hao H, Wang L, Chen H, et al. YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition. Am J Transl Res. 2017;9(8):3749–3757.
   PubMed Web of Science ®Google Scholar
• Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA interactions. Methods Mol Biol. 2016;1402:271‐286. doi:10.1007/978-1-4939-3378-5_21
   PubMedGoogle Scholar
• Ferrè F, Colantoni A, Helmer-Citterich M. Revealing protein-lncRNA interaction. Brief Bioinform. 2016;17(1):106‐116. doi:10.1093/bib/bbv031
   PubMed Web of Science ®Google Scholar
• Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014;65(6):1140–1151. doi:10.1016/j.eururo.2013.12.003
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tang L. The application of lncRNAs in cancer treatment and diagnosis. Recent Pat Anticancer Drug Discov. 2018;13(3):292–301. doi:10.2174/1574892813666180226121819
   PubMed Web of Science ®Google Scholar
• Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661–5667. doi:10.1038/onc.2017.184
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen X, Xie R, et al. DANCR promotes metastasis and proliferation in bladder cancer cells by enhancing IL-11-STAT3 signaling and CCND1 expression. Mol Ther. 2019;27(2):326–341. doi:10.1016/j.ymthe.2018.12.015
   PubMed Web of Science ®Google Scholar
• Gu P, Chen X, Xie R, et al. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer. Mol Cancer. 2019;18(1):109. doi:10.1186/s12943-019-1037-8
   PubMedGoogle Scholar
• Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013;45(11):1392–1398. doi:10.1038/ng.2771
   PubMed Web of Science ®Google Scholar
• Zhang A, Zhao JC, Kim J, et al. LncRNA HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer. Cell Rep. 2015;13(1):209–221. doi:10.1016/j.celrep.2015.08.069
   PubMed Web of Science ®Google Scholar
• Yu Y, Chen Y, Zhang X, et al. Knockdown of lncRNA KCNQ1OT1 suppresses the adipogenic and osteogenic differentiation of tendon stem cell via downregulating miR-138 target genes PPARγ and RUNX2. Cell Cycle. 2018;17(19–20):2374–2385. doi:10.1080/15384101.2018.1534510
   PubMed Web of Science ®Google Scholar
• Zhang S, Ma H, Zhang D, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9(7):742. doi:10.1038/s41419-018-0793-5
   PubMedGoogle Scholar
• Guo B, Zhang Q, Wang H, et al. KCNQ1OT1 promotes melanoma growth and metastasis. Aging (Albany NY). 2018;10(4):632–644. doi:10.18632/aging.101418
   PubMedGoogle Scholar
• Li Y, Li C, Li D, et al. lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway. Onco Targets Ther. 2019;12:2649–2660. doi:10.2147/OTT.S188054
   PubMed Web of Science ®Google Scholar
• Cheng P, Lu P, Guan J, et al. LncRNA KCNQ1OT1 controls cell proliferation, differentiation and apoptosis by sponging miR-326 to regulate c-Myc expression in acute myeloid leukemia. Neoplasma. 2020;67(2):238–248. doi:10.4149/neo_2018_181215N972
   PubMed Web of Science ®Google Scholar
• Chen QH, Li B, Liu DG, et al. LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1. Cancer Cell Int. 2020;20(1):394. doi:10.1186/s12935-020-01481-8
   PubMed Web of Science ®Google Scholar
• Wang K, Jin W, Jin P, et al. miR-211-5p suppresses metastatic behavior by targeting SNAI1 in renal cancer. Mol Cancer Res. 2017;15(4):448–456. doi:10.1158/1541-7786.MCR-16-0288
   PubMed Web of Science ®Google Scholar
• Jiang G, Wen L, Deng W, Jian Z, Zheng H. Regulatory role of miR-211-5p in hepatocellular carcinoma metastasis by targeting ZEB2. Biomed Pharmacother. 2017;90:806–812. doi:10.1016/j.biopha.2017.03.081
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Databaseissue):D92–D97. doi:10.1093/nar/gkt1248
   PubMed Web of Science ®Google Scholar
• Gu P, Chen X, Xie R, et al. lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5. Mol Ther. 2017;25(8):1959–1973. doi:10.1016/j.ymthe.2017.04.016
   PubMed Web of Science ®Google Scholar
• Kang Y, Jia Y, Wang Q, et al. Long noncoding RNA KCNQ1OT1 promotes the progression of non-small cell lung cancer via regulating miR-204-5p/ATG3 axis. Onco Targets Ther. 2019;12:10787–10797. doi:10.2147/OTT.S226044
   PubMed Web of Science ®Google Scholar
• Feng W, Wang C, Liang C, et al. The dysregulated expression of KCNQ1OT1 and Its interaction with downstream factors miR-145/CCNE2 in breast cancer cells. Cell Physiol Biochem. 2018;49(2):432–446. doi:10.1159/000492978
   PubMedGoogle Scholar
• Wang J, Zhang H, Situ J, Li M, Sun H. KCNQ1OT1 aggravates cell proliferation and migration in bladder cancer through modulating miR-145-5p/PCBP2 axis. Cancer Cell Int. 2019;19(1):325. doi:10.1186/s12935-019-1039-z
   PubMed Web of Science ®Google Scholar
• Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S. MicroRNAs in prostate cancer: functional role as biomarkers. Cancer Lett. 2017;407:9–20. doi:10.1016/j.canlet.2017.08.011
   PubMed Web of Science ®Google Scholar
• Yarahmadi S, Abdolvahabi Z, Hesari Z, et al. Inhibition of sirtuin 1 deacetylase by miR-211-5p provides a mechanism for the induction of cell death in breast cancer cells. Gene. 2019;711:143939. doi:10.1016/j.gene.2019.06.029
   PubMed Web of Science ®Google Scholar
• Liang M, Jia J, Chen L, et al. LncRNA MCM3AP-AS1 promotes proliferation and invasion through regulating miR-211-5p/SPARC axis in papillary thyroid cancer. Endocrine. 2019;65(2):318–326. doi:10.1007/s12020-019-01939-4
   PubMed Web of Science ®Google Scholar
• Díaz-Martínez M, Benito-Jardón L, Alonso L, Koetz-Ploch L, Hernando E, Teixidó J. miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma. Cancer Res. 2018;78(4):1017–1030. doi:10.1158/0008-5472.CAN-17-1318
   PubMed Web of Science ®Google Scholar
• Liu S, Wang H, Mu J, et al. MiRNA-211 triggers an autophagy-dependent apoptosis in cervical cancer cells: regulation of Bcl-2. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(3):359–370. doi:10.1007/s00210-019-01720-4
   PubMed Web of Science ®Google Scholar
• Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55(6):221–227. doi:10.1007/s00011-006-0076-y
   PubMed Web of Science ®Google Scholar
• Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol. 1993;32(11):949–955. doi:10.1093/rheumatology/32.11.949
   PubMedGoogle Scholar
• Johansen JS, Krabbe KS, Møller K, Pedersen BK. Circulating YKL-40 levels during human endotoxaemia. Clin Exp Immunol. 2005;140(2):343–348. doi:10.1111/j.1365-2249.2005.02763.x
   PubMed Web of Science ®Google Scholar
• Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53(2):172–209.
   PubMed Web of Science ®Google Scholar
• De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun. 2001;285(4):926–931. doi:10.1006/bbrc.2001.5253
   PubMed Web of Science ®Google Scholar